CN1178679A - Chinese drug capsule for curing tetanic spondylitis and lumber vertebra hypertrophic hyperosteogeny - Google Patents

Chinese drug capsule for curing tetanic spondylitis and lumber vertebra hypertrophic hyperosteogeny Download PDF

Info

Publication number
CN1178679A
CN1178679A CN 96119456 CN96119456A CN1178679A CN 1178679 A CN1178679 A CN 1178679A CN 96119456 CN96119456 CN 96119456 CN 96119456 A CN96119456 A CN 96119456A CN 1178679 A CN1178679 A CN 1178679A
Authority
CN
China
Prior art keywords
radix
rhizoma
parts
hyperosteogeny
spondylitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 96119456
Other languages
Chinese (zh)
Inventor
赵广钧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN 96119456 priority Critical patent/CN1178679A/en
Publication of CN1178679A publication Critical patent/CN1178679A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The Chinese drug capsule is compounded with Caulis Sinomenii, prepared Radix aconiti, reticulate millettia, Cortex Erythrnae, Astragalus membranaceus and other 16 kinds of Chinese medicinal materials. It has fast and high cure effect on tetanic spondylitis and hypertrophic hyperosteogeny of cervical vertebra, thoracic vertabra and lumber vertebra without toxic side effect. It is widely used in curing bone and joint diseases caused by arthralgia arthralgia due to wind, cold and wetness evil.

Description

The Chinese medicinal capsule of treatment ankylosing spondylitis, hyperosteogeny bone matrix hyperplasia
The present invention relates to a kind of pharmaceutical product that is shaped as feature with specific physical, particularly treat the Chinese medicinal capsule of ankylosing spondylitis, neck, breast, hyperosteogeny bone matrix hyperplasia, be the patient's of the sclerotin that causes because of anemofrigid-damp arthralgia of treatment and arthropathy choice drug, also effective to rheumatism, rheumatoid.
Ankylosing spondylitis, neck, breast, the hyperosteogeny bone matrix hyperplasia is a big illness that threatens human health, become one of important topic that medical circle research captures, people suffer from above-mentioned disease, not only suffer ailing the torment, obstinate, and have but cause lifelong maimed person, so so, be because the emphasis for the treatment of above-mentioned disease is at treatment rheumatism in the past, medication on the rheumatoid, and often ignored at benefiting qi and nourishing blood, strengthening the body resistance, the medication of human body immunity improving power aspect, it is long to cause showing clinically its course of treatment, the side effect of damage Liver and kidney is obvious, and the little situation of proving effective.
The object of the present invention is to provide that a kind of preparation technology is simple, cost is low, to indication short treating period instant effect, cure rate height, cure the Chinese medicinal capsule that is difficult for recurrence, the treatment ankylosing spondylitis that has no side effect, neck, breast, hyperosteogeny bone matrix hyperplasia.
Composition of the present invention and ratio of weight and number are as follows:
Caulis Sinomenii: Radix Aconiti Preparata: Caulis Spatholobi: Cortex erythrinae: Cornu Cervi Degelatinatum: the Radix Astragali: Herba Epimedii: Radix Codonopsis: the Rhizoma Atractylodis Macrocephalae: Radix Angelicae Sinensis: Rhizoma Chuanxiong: Rhizoma Cibotii: Olibanum: Myrrha: Radix Paeoniae Rubra: Rhizoma Cyperi: Rhizoma Et Radix Notopterygii: Radix Saposhnikoviae: Ramulus Cinnamomi: Herba Asari: the Radix Angelicae Dahuricae=, (4-6):, (4-6):, (4-6):, (6-9):, (11-14):, (14-16):, (8-12):, (6-9):, (6-9):, (4-6):, (4-6):, (6-9):, (4-6):, (4-6):, (4-6):, (4-6):, (4-6):, (4-6):, (4-6): 1:, (4-6).
Clinical practice by for many years and studies show that, rheumatism, rheumatoid just cause the risk factor of ankylosing spondylitis, neck, breast, hyperosteogeny bone matrix hyperplasia, and morbific main cause is because of its body void usually, body resistance against diseases is low, the gas that battalion defends is uncomfortable, interspaces of skin and muscles being loose, and the heresy that wind and cold is wet is taken advantage of a weak point, due to the infringement meridians, multiple abscess joint.Such as women puerperal, prolonged illness, wound, often catch a cold and personnel such as autoimmune insufficiency easily suffer from described disease.Based on above-mentioned cognition, then obstructed according to pain, general rule not bitterly, control wind and control blood earlier, the blood sector-style is from going out, cold then heat, wet then profit, harmonizing yingfen and weifen, the theory of Chinese medical science of strengthening the body resistance, dialectical executing controlled, and starts with from human body integral and nourishes blood and seek, expelling wind and removing dampness, the detumescence eliminating impediment, promoting the circulation of QI to relieve pain, strengthening the body resistance is realized the purpose for the treatment of both the principal and secondary aspects of a disease.Thereby on medication and compatibility relationship, demonstrate fully above-mentioned Therapeutic Principle, and reuse product unconventional escalated dose on its consumption of tonification, make its effect rapidly lasting, can QI invigorating and body resistance strengthening consolidate such as the adding of Cornu Cervi Degelatinatum, Herba Epimedii, the Radix Astragali, Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae; Adding again can expelling wind and removing dampness, the Caulis Sinomenii of dredge the meridian passage, Radix Aconiti Preparata, Caulis Spatholobi, Cortex erythrinae; The introducing of Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Cibotii, Olibanum, Myrrha, Radix Paeoniae Rubra, Rhizoma Cyperi can nourishing blood and promoting blood circulation, and being equipped with can harmonizing yingfen and weifen again, Rhizoma Et Radix Notopterygii, Radix Saposhnikoviae, Ramulus Cinnamomi, Herba Asari, the Radix Angelicae Dahuricae of detumescence eliminating impediment.It is scientific and reasonable through clinical further checking for the compatibility of above-mentioned kinds of traditional Chinese medicines, definite effect.
Content of the present invention is further described by embodiment:
Example 1, get 4 parts of Caulis Sinomeniis, 5 parts of Radix Aconiti Preparatas, 6 portions of Caulis Spatholobis, 7 parts of Cortex erythrinaes, 11 parts of Cornu Cervi Degelatinatums, 16 parts of Radixs Astragali, 10 parts of Herba Epimedii, 6 parts of Radix Codonopsis, 9 parts of Rhizoma Atractylodis Macrocephalaes, 5 parts of Radix Angelicae Sinensis, 4 parts of Rhizoma Chuanxiongs, 8 parts of Rhizoma Cibotii, 6 parts of Olibanums, 5 parts of Myrrhas, 4 parts of Radix Paeoniae Rubra, 6 portions of Rhizoma Cyperis, 5 portions of Rhizoma Et Radix Notopterygiis, 4 parts of Radix Saposhnikoviaes, 5 parts of Ramulus Cinnamomi, 1 part of Herba Asari and 6 parts of Radixs Angelicae Dahuricae, encapsulated through the Powdered medicament mixed of pulverize separately, after stirring.Every 0.25 gram.
Example 2, learn from else's experience be ground into 6 parts of pulverous Caulis Sinomeniis, 4 parts of Radix Aconiti Preparatas, 5 parts of Caulis Spatholobis, 6 parts of Cortex erythrinaes, 14 parts of Cornu Cervi Degelatinatums, 15 parts of the Radixs Astragali, 8 parts of Herba Epimedii, 7 parts of Radix Codonopsis, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 6 parts of Radix Angelicae Sinensis, 5 parts of Rhizoma Chuanxiongs, 6 parts of Rhizoma Cibotii, 5 parts of Olibanums, 6 parts of Myrrhas, 5 parts of Radix Paeoniae Rubra, 5 parts of Rhizoma Cyperis, 4 parts of Rhizoma Et Radix Notopterygiis, 6 parts of Radix Saposhnikoviaes, 4 parts of Ramulus Cinnamomi, 1 part of Herba Asari and the Radix Angelicae Dahuricae be mixed for 4 parts stir encapsulated.Every 0.5 gram.
Example 3, learn from else's experience be ground into 5 parts of pulverous Caulis Sinomeniis, 6 parts of Radix Aconiti Preparatas, 4 parts of Caulis Spatholobis, 9 parts of Cortex erythrinaes, 12 parts of Cornu Cervi Degelatinatums, 14 parts of the Radixs Astragali, 12 parts of Herba Epimedii, 9 parts of Radix Codonopsis, 7 parts of the Rhizoma Atractylodis Macrocephalaes, 4 parts of Radix Angelicae Sinensis, 6 parts of Rhizoma Chuanxiongs, 9 parts of Rhizoma Cibotii, 4 parts of Olibanums, 4 parts of Myrrhas, 6 parts of Radix Paeoniae Rubra, 4 parts of Rhizoma Cyperis, 6 parts of Rhizoma Et Radix Notopterygiis, 5 parts of Radix Saposhnikoviaes, 6 parts of Ramulus Cinnamomi, 1 part of Herba Asari and the Radix Angelicae Dahuricae be mixed for 5 parts stir encapsulated.Every 0.25 gram.
Use obey time three times, each 4-6 grain, 30 days is a course of treatment, anemia of pregnant woman's forbidding.
The present invention compared with prior art since pathogenesis diagnosis accurately, scientific composition, medication be reasonable, Thereby clinical manifestation its treat both principal and secondary aspect of disease, can eliminate ailing the torment and can make again the sclerotin pine dredge the hypertrophy position Reposition, tetanic spondylitis are recovered slight motor function, its efficient reaching more than 98%, to indication Instant effect, short treating period, curative effect be lasting, cure the advantage that is difficult for recurrence, have no side effect, the while preparation technology Simply, cost is low, obviously reduce patient's financial burden, be beneficial to and apply.

Claims (2)

1. Chinese medicinal capsule for the treatment of ankylosing spondylitis, neck, breast, hyperosteogeny bone matrix hyperplasia is characterized in that forming with ratio of weight and number as follows:
Caulis Sinomenii: Radix Aconiti Preparata: Caulis Spatholobi: Cortex erythrinae: Cornu Cervi Degelatinatum: the Radix Astragali: Herba Epimedii: Radix Codonopsis: the Rhizoma Atractylodis Macrocephalae: Radix Angelicae Sinensis: Rhizoma Chuanxiong: Rhizoma Cibotii: Olibanum: Myrrha: Radix Paeoniae Rubra: Rhizoma Cyperi: Rhizoma Et Radix Notopterygii: Radix Saposhnikoviae: Ramulus Cinnamomi: Herba Asari: the Radix Angelicae Dahuricae=, (4-6):, (4-6):, (4-6):, (6-9):, (11-14):, (14-16):, (8-12):, (6-9):, (6-9):, (4-6):, (4-6):, (6-9):, (4-6):, (4-6):, (4-6):, (4-6):, (4-6):, (4-6):, (4-6): 1:, (4-6).
2. Chinese medicinal capsule according to claim 1 is characterized in that forming with ratio of weight and number as follows:
Caulis Sinomenii: Radix Aconiti Preparata: Caulis Spatholobi: Cortex erythrinae: Cornu Cervi Degelatinatum: the Radix Astragali: Herba Epimedii: Radix Codonopsis: the Rhizoma Atractylodis Macrocephalae: Radix Angelicae Sinensis: Rhizoma Chuanxiong: Rhizoma Cibotii: Olibanum: Myrrha: Radix Paeoniae Rubra: Rhizoma Cyperi: Rhizoma Et Radix Notopterygii: Radix Saposhnikoviae: Ramulus Cinnamomi: Herba Asari: the Radix Angelicae Dahuricae=5: 6: 4: 9: 12: 14: 12: 9: 7: 4: 6: 9: 4: 4: 6: 4: 6: 5: 6: 1: 5.
CN 96119456 1996-10-07 1996-10-07 Chinese drug capsule for curing tetanic spondylitis and lumber vertebra hypertrophic hyperosteogeny Pending CN1178679A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 96119456 CN1178679A (en) 1996-10-07 1996-10-07 Chinese drug capsule for curing tetanic spondylitis and lumber vertebra hypertrophic hyperosteogeny

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 96119456 CN1178679A (en) 1996-10-07 1996-10-07 Chinese drug capsule for curing tetanic spondylitis and lumber vertebra hypertrophic hyperosteogeny

Publications (1)

Publication Number Publication Date
CN1178679A true CN1178679A (en) 1998-04-15

Family

ID=5125712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 96119456 Pending CN1178679A (en) 1996-10-07 1996-10-07 Chinese drug capsule for curing tetanic spondylitis and lumber vertebra hypertrophic hyperosteogeny

Country Status (1)

Country Link
CN (1) CN1178679A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100361680C (en) * 2005-09-12 2008-01-16 董伟胜 Medicine for treating backbone disease
CN102018792A (en) * 2010-11-19 2011-04-20 王丽华 Traditional Chinese medicine for treating ankylosing spondylitis
CN104997897A (en) * 2015-07-31 2015-10-28 成都市飞龙水处理技术研究所 Decoction drug for treating rheumatoid lumbar hypertrophy and preparation method thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100361680C (en) * 2005-09-12 2008-01-16 董伟胜 Medicine for treating backbone disease
CN102018792A (en) * 2010-11-19 2011-04-20 王丽华 Traditional Chinese medicine for treating ankylosing spondylitis
CN102018792B (en) * 2010-11-19 2012-09-12 王丽华 Traditional Chinese medicine for treating ankylosing spondylitis
CN104997897A (en) * 2015-07-31 2015-10-28 成都市飞龙水处理技术研究所 Decoction drug for treating rheumatoid lumbar hypertrophy and preparation method thereof

Similar Documents

Publication Publication Date Title
CN100361704C (en) Medicated wine for treating rheumatosis and osteoarthropathy
CN102091295B (en) Chinese medicinal composition for treating femoral head necrosis and preparation method thereof
CN101130005A (en) Traditional Chinese medicine for treating blahs aypnia after hepatocerebral apoplexy
CN1099983A (en) Medicine for treating rheumatoid or rheumatic arthritis and hyperosteogeny, and method for preparing same
CN101152331A (en) Traditional Chinese medicine for treating Qi asthenia type hemorrhoid hemorrhage
CN1237427A (en) Adhesive plaster for curing prolapse of lumbar intervertebral disk
CN101129617A (en) Traditional Chinese medicine for treating cirrhosis
CN1332702C (en) Medicine for treating psoriasis
CN101590104A (en) A kind of Chinese medicine for the treatment of obstructive angiitis
CN101690768B (en) Vein and artery relieving pills for impediment of sinew
CN101134065A (en) Traditional Chinese medicine for treating intestinal obstruction
CN1317021C (en) Chinese medicinal formulation for stopping pain for removing Bi
CN101130052A (en) Traditional Chinese medicine for treating post partum paralysis
CN101167932A (en) Traditional Chinese medicine for treating chronic hepatitis B
CN101129893A (en) Traditional Chinese medicine for treating cervical vertebra disease combined with diarrhea
CN1178679A (en) Chinese drug capsule for curing tetanic spondylitis and lumber vertebra hypertrophic hyperosteogeny
CN101129596A (en) Traditional Chinese medicine for treating joint pain
CN103721082A (en) Traditional Chinese medicinal composition for treating scapulohumeral periarthritis
CN1067571C (en) Chinese medicine capsule for treating lumbar and cervical protrusion
CN101940726B (en) Medicament for treating tourette syndrome
CN1217202A (en) Medicine for treating rheumatic diseases
CN101837111A (en) Medicament for curing proliferation of mammary glands and preparation method thereof
CN101284087B (en) Medicinal composition for curing lumbar disease
CN101129709A (en) Traditional Chinese medicine for treating obsolete bone fracture lumbago of the elderly
CN1219402A (en) Chinese medicinal pill for curing rheumatism and rheumatoid disease and its preparation method

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication